about
Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13.How will interventional oncology navigate the "valleys of death" for new medical devices?Comparison of reporting phase I trial results in ClinicalTrials.gov and matched publications.Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration.Role of cooperative groups and funding source in clinical trials supporting guidelines for systemic therapy of breast cancer.
P2860
description
2016 nî lūn-bûn
@nan
2016 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
name
Relevance of randomised controlled trials in oncology.
@ast
Relevance of randomised controlled trials in oncology.
@en
type
label
Relevance of randomised controlled trials in oncology.
@ast
Relevance of randomised controlled trials in oncology.
@en
prefLabel
Relevance of randomised controlled trials in oncology.
@ast
Relevance of randomised controlled trials in oncology.
@en
P2093
P1433
P1476
Relevance of randomised controlled trials in oncology
@en
P2093
Arnoud J Templeton
Bostjan Seruga
Christopher M Booth
Francisco Vera-Badillo
Ian F Tannock
Saroj Niraula
P304
P356
10.1016/S1470-2045(16)30572-1
P577
2016-12-01T00:00:00Z